‘The blue one takes a battering’ why do young adults with asthma overuse bronchodilator inhalers? A qualitative study

Sue Cole,1 Clive Seale,2 Chris Griffiths3

ABSTRACT

Objective: Overuse of short-acting bronchodilators is internationally recognised as a marker of poor asthma control, high healthcare use and increased risk of asthma death. Young adults with asthma commonly overuse short-acting bronchodilators. We sought to determine the reasons for overuse of bronchodilator inhalers in a sample of young adults with asthma.

Design: Qualitative study using a purposive extreme case sample.

Setting: A large urban UK general practice.

Participants: Twenty-one adults with moderate asthma, aged 20–32 years. Twelve were high users of short-acting bronchodilators, nine were low users.

Results: Asthma had a major impact on respondents’ lives, disrupting their childhood, family life and career opportunities. High users of short-acting bronchodilators had adapted poorly to having asthma and expressed anger at the restrictions they experienced. Overuse made sense to them: short-acting bronchodilators were a rapid, effective, cheap ‘quick-fix’ for asthma symptoms. High users had poorer control of asthma and held explanatory models of asthma which emphasised short-term relief via bronchodilation over prevention. Both high and low users held strong views about having to pay for asthma medication, with costs cited as a reason for not purchasing anti-inflammatory inhalers.

Conclusions: Young adults who were high users of short-acting bronchodilators had adapted poorly to having asthma and had poor asthma control. They gave coherent reasons for overuse. Strategies that might address high bronchodilator use in young adults include improving education to help young people accept and adapt to their illness, reducing stigmatisation and providing free asthma medication to encourage the use of anti-inflammatory inhalers.

INTRODUCTION

In total, 300 million people are estimated worldwide to suffer from asthma. Despite the availability of effective treatments, poor asthma control is widespread in Europe, Asia and North America. Frequent use of short-acting β2 agonist inhalers is internationally recognised as a marker of poor asthma control, increased risk of hospital admission and death from asthma. The serum salbutamol levels in those dying from asthma are, on average, more than double those of controls of equivalent asthma severity. The risks of oral corticosteroid course, emergency room attendance and hospitalisation rise progressively with increasing numbers of short-acting bronchodilator inhalers dispensed per year. Excess healthcare use, notably hospitalisation, increases the societal and healthcare costs of asthma markedly. Reduced healthcare costs are associated with good control of asthma.

A cross-sectional analysis of prescribing data shows that an overuse of short-acting bronchodilators is common in young adults.
Why do young adults with asthma overuse bronchodilator inhalers?

Thirty-nine per cent of Danish adults, aged 22–44 years, from a large regional prescribing database, used bronchodilators as monotherapy.\textsuperscript{8} Within a cohort of nearly 10 000 Canadians with asthma aged 15–34 years, 37% were using no inhaled corticosteroids, and 7% were using more than 12 canisters of bronchodilators per year.\textsuperscript{4}

Asthma in adolescence, the period between the onset of puberty and attaining an independent responsible role in society,\textsuperscript{13} has received considerable attention, see, for example, Shah\textsuperscript{14} and Gabe,\textsuperscript{15} but little work has focused on young adulthood.

Despite the repeated documentation of bronchodilator overuse in observational studies across continents and over several decades,\textsuperscript{3,10} little is understood about why people, and young adults in particular, overuse their bronchodilator inhalers. We therefore sought, using qualitative methods, to examine the experiences of young adults who overused short-acting bronchodilator inhalers. We aimed to gain insight into reasons for their overuse.

METHODS
The study was set in a large urban general practice in the UK. We used purposive sampling to obtain an extreme case sample of patients using high and low amounts of short-acting bronchodilators. We searched computerised practice medical records to identify young adults with asthma aged 20–32 years, their prescriptions for short-acting bronchodilators and other asthma medication and their clinical and demographic characteristics. We identified patients at step 2 (ie, co-prescribed inhaled steroids) or above of the British Asthma Guidelines.\textsuperscript{10} We defined high users of bronchodilators as those who had received three or more short-acting bronchodilators in the last 3 months, and low users as those prescribed two or less in the last 3 months. We wrote to potential participants giving details of the study and inviting them to take part. We aimed to broadly match the high users and low users as far as possible with respect to a range of variables including: age, gender, BTS treatment step, duration of asthma diagnosis, smoking status and visits to accident and emergency departments and hospitalisations for asthma. We reviewed the sample as the study progressed to monitor and control the evolving composition of the groups. Patients who responded to our written invitation to the study were invited to meet with the researcher (SC) to obtain full details and to give written informed consent. The North and Mid Essex Local Research Ethics Committee approved the study (REC MH428). The study was funded by the East London and Essex Network for Research. The sponsor and funder had no influence on the design, analysis or writing.

Interviews
SC carried out semistructured depth interviews with 21 informants. Eighteen were carried out within the surgery premises in a small private room and three within the subjects’ own home for their own convenience, for reasons of childcare. Interviews lasted for about an hour and were recorded and then transcribed verbatim with the respondents’ permission.

We developed a topic guide on the basis of the existing literature and our experience in qualitative research in asthma. This was refined during the first few interviews and covered areas including:

- Early memories of asthma diagnosis and treatment;
- Experiences and behaviour during asthma exacerbations;
- Impact of asthma on recreation and choices of careers;
- Explanatory models of asthma;
- Attitudes to medication and views on the role and use of medication, particularly inhaled therapy;
- Relationships with health professionals;
- Social and family networks;
- Trade-offs between the use of medication and other methods of control;
- Emotional responses to asthma.

Field notes were taken, and the researcher recorded general observations of each respondent’s attitude and behaviour.

Analysis
We used the Framework approach to analyse data.\textsuperscript{16} This involves a series of five key stages: familiarisation, identifying a thematic framework, indexing, charting, mapping and interpretation. Software for qualitative data analysis (MAXQDA) was used to assist data handling. The thematic analysis was developed by two of the authors (SC and CG) who jointly coded all transcripts and resolved differences of interpretation as the analysis progressed. As a validity check, a third author (CS, a medical sociologist) independently read transcripts and identified no additional themes. The six themes that emerged from the data covering all 21 respondents comprised: impact of asthma, coping, stigma, explanatory models, rationalisation of inhaler use and costs. We created charts for each theme, cross-tabulating coded text for each against respondents.

RESULTS
Table 1 describes the sample interviewed. All were between 20 and 32 years of age. Most of the respondents were leading lives fairly typical of this age group; some were studying, others were in early careers, or they had young families or responsibilities for ill parents.

Impact of asthma on respondents’ lives
Asthma had a major impact on the lives of most respondents. They described how asthma had restricted their childhood and disrupted the course of their lives (box 1). Examples included having to change schools,
and altering employment opportunities, sometimes dashing hopes of a chosen career.

Asthma had implications for the social and personal lives of these young adults. Stigma was common; respondents described being ‘excluded from team activities, football and things like that’, and ‘just wanting to be like the rest and not to have to stop and put this thing in my mouth’. Asthma was ‘so embarrassing’ and inhalers were something ‘to hide in a bag’.

These young adults gave candid descriptions of the restrictions they experienced, including the avoidance of wearing tight, fashionable clothes that could restrict the breathing, difficulties when dancing at clubs, the inability to stay over at friends’ after a night out because bronchodilators had been forgotten, and the embarrassment of needing to use a bronchodilator during sexual intercourse (box 2).

Asthma attacks were frightening, life-threatening experiences (box 3).

An adverse impact of asthma was more often reported by high users of short-acting bronchodilators. Anger or resentment at having asthma was mentioned by 8 of 12 high users, but only 1 (who described ‘irritation’) of 9 low users. Other frustrations were the failure to find a cure, and the stigmatisation that they felt (boxes 4 and 5).

By contrast, despite similar experiences of asthma, low users did not express anger about their illness, describing it as something that was accepted and part of their lives (box 6). Sometimes, this normalisation reflected

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Characteristics of informants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low users of short-acting bronchodilators</td>
<td>High users of short-acting bronchodilators</td>
</tr>
<tr>
<td>Number interviewed</td>
<td>9</td>
</tr>
<tr>
<td>Mean age (range)</td>
<td>27.4 years (22–30)</td>
</tr>
<tr>
<td>Mean age at diagnosis (range)</td>
<td>9.3 years (1–19)</td>
</tr>
<tr>
<td>Female</td>
<td>4</td>
</tr>
<tr>
<td>Preventer inhalers (mean/year)</td>
<td>6</td>
</tr>
<tr>
<td>Number on BTS step 2: step 3</td>
<td>4.5</td>
</tr>
<tr>
<td>Number on ICS/LABA inhalers</td>
<td>5</td>
</tr>
<tr>
<td>Oral steroids for asthma ever</td>
<td>3</td>
</tr>
<tr>
<td>Oral steroids in last year</td>
<td>1</td>
</tr>
<tr>
<td>A&amp;E attendance for asthma ever</td>
<td>3</td>
</tr>
<tr>
<td>A&amp;E attendance in last year</td>
<td>0</td>
</tr>
<tr>
<td>Admission for asthma ever</td>
<td>2</td>
</tr>
<tr>
<td>Admission in last year</td>
<td>0</td>
</tr>
<tr>
<td>Current smoker</td>
<td>4</td>
</tr>
<tr>
<td>Had a self-management plan</td>
<td>6</td>
</tr>
<tr>
<td>Pays for prescriptions</td>
<td>8</td>
</tr>
</tbody>
</table>

BTS, British Thoracic Society; ICS, inhaled corticosteroid; LABA, long acting beta agonist.
the influence of other family members with asthma. Parental attitudes may have been important, with low users reporting positive attitudes of parents to their illness, and high users reporting negative responses.

Asthma control, explanatory models and medication use

High users often reported poor control of their asthma symptoms (box 7). Of the 12 high users, 2 rated their asthma as mild, 8 as moderate and the remaining 2 as ‘moderate-to-severe’; of the 9 low users, 6 reckoned their asthma to be mild and 3 to be moderate. Although respondents from both groups described always having a bronchodilator with them, high users reported ‘having them everywhere’ and being ‘panicky’ without one, with elaborate arrangements for having access to bronchodilators. These included having multiple bronchodilator inhalers at different sites (handbag, car, house, partner’s...

---

**Box 3** Respondents’ experiences of asthma attacks

<table>
<thead>
<tr>
<th>Respondent</th>
<th>Experience</th>
</tr>
</thead>
<tbody>
<tr>
<td>30f 11-12 High user</td>
<td>I was out playing once and I started to get really, really tight chested and it got really bad and I think I started to panic as well, which made it worse, and it got to the point where I was really, really struggling for breath and I probably...bad thing to do umm over used my inhaler just to clear it, which it did, I think it was about ten to fifteen minutes and it was very, very, very scary.</td>
</tr>
<tr>
<td>26f 17-2 Low user</td>
<td>That’s the biggest thing is not to panic but it’s like...I’ve always described it as it’s like drowning but you’re drowning in air because you can’t get it. It’s like being six foot underneath the water and you know air is up there and you can’t get it.</td>
</tr>
</tbody>
</table>

**Box 5** Restrictions and stigma arising from asthma

<table>
<thead>
<tr>
<th>Respondent</th>
<th>Experience</th>
</tr>
</thead>
<tbody>
<tr>
<td>27f 9-9 High user</td>
<td>I’m angry with the way people look at people with asthma because it’s still quite a...like I say it’s either people are overly in your face about it or pretend it doesn’t happen and a lot of people will say to me ‘oh you can’t do that, you’ve got asthma’ and I think ‘how dare you tell me I can’t do something without letting me have a go at it first’. I suppose I feel a bit angry with being dealt with it when what I always wanted to do was farming and it has restricted me from doing it.</td>
</tr>
</tbody>
</table>

**Box 4** Anger at having asthma

<table>
<thead>
<tr>
<th>Respondent</th>
<th>Experience</th>
</tr>
</thead>
<tbody>
<tr>
<td>32f 1-16 High user</td>
<td>I’m angry with having asthma.</td>
</tr>
<tr>
<td>27f 9-9 High user</td>
<td>Do you feel angry about having asthma? Yes. I think, why me? I must admit, yes, I have a 6ft 2 brother who’s in perfect health; there’s nothing ever been wrong with him and you think, why me?</td>
</tr>
<tr>
<td>29f 6-9 Low user</td>
<td>Yeah, yeah I mean asthma’s nothing unusual to me. That’s just part of life really (laughter) and that’s the sort of thing...as I say my father’s is worse than mine and my brother’s also asthmatic but his isn’t as bad as mine so.</td>
</tr>
</tbody>
</table>

**Box 6** Acceptance of asthma by low users

<table>
<thead>
<tr>
<th>Respondent</th>
<th>Experience</th>
</tr>
</thead>
<tbody>
<tr>
<td>23f 7-9 Low user</td>
<td>It doesn’t now. I’m so used to it now, I don’t even think about it really.</td>
</tr>
<tr>
<td>29f 12-7 Low user</td>
<td>My mother’s always...you know she started me off making sure I was using those at home but it was something that, as I say, I knew that I could get on and do things providing I took the medication and if I didn’t take the medication, then I was going to be sat at home wheezing.</td>
</tr>
</tbody>
</table>
Box 7  Asthma control

The blue one takes a battering, it really does and that’s probably not the best way of doing things but it’s the only way I think...I mean...If it’s the only way you can be comfortable, then that’s what you’ve got to do.

17-10 High user

It was when I sat my GCSEs I really...that’s because I was incredibly ill, because I think my asthma’s also brought on by stress as well. I start hyperventilating and things like that, and that was horrific.

30f11-9 High user

I don’t use the blue inhaler at the moment, no. Well, at the moment, it feels like I’ve never had asthma—it feels like I haven’t got it.

29m 19-4 Low user

Once I got onto the Serevent and Flixotide, then that controlled it much better, and these days I’d use a Ventolin two, three times a year probably.

29f 21-2 Low user

Box 8  Explanatory models of asthma in high and low users

HIGH USERS:
It’s something to do with the airways closing up and different things can trigger it like stress or anything—I just can’t remember much of what the doc told me, I just got told basically the inhalers are there to help you and just use them when you need to and they basically gave me instruction on how to.

25f 4-1 High user

The inside of your lungs—when you breathe—they close up so the air can’t...I think the oxygen goes in and then it goes into your lungs and into your blood and I just think they get...closed up or blocked off and the inhaler just opens them up. I’m probably completely wrong ...

26f 17-3 High user

Interviewer: What does the brown inhaler do? Respondent: I’m not too sure to be honest with you umm I’ve often thought that it actually coated your lungs with something.

26f 17-3 High user


20f 16-4 High user

I have a red one and a brown one at the moment. They’re long-lasting ones—I think.

29f 5-4 High user

LOW USERS:
When it’s the first time, I take the Bricanyl inhaler as it sort of opens the airways. With the Flixotide, it’s just generally used so it keeps the inflammation in the tubes down.

30f 2-7 Low user

The brown one? Well, it doesn’t open up the—it doesn’t dilate it in the same way, does it? It works through—a bit like adrenal hormones by reducing, not...inflammation, is it?

29m 6-3 Low user

Box 9  Primacy of short-acting bronchodilator inhalers for high users

I think it’s [the blue inhaler] probably for, you know, for young people, I think what it is is that the purple one is more of a build up isn’t it really umm and the blue one’s just a quick fix to fix your lungs or whatever quickly so you can just have a couple of squirts and get back to what you’re doing as opposed to doing the purple one and having to wait X amount or do it and get built up and...even though it’s still running in the background, you know umm the blue one’s good because you can just have a couple of squirts and get back to whatever you’re doing.

17-12 High user

I know that I’ve just got to have it [salbutamol] and silly little things like making sure I’ve got enough in the drawer because if it runs out then I’ve got to worry about getting another one because I would not go a day...The blue, yeah the reliever, I just have...it is quite a thing that I need to think about all the time.

27f 10-6 High user

The blue stops what’s happening, happening straight away, where the preventative...you sometimes forget, it’s at the back of your mind and you forget to use it...I think mainly that’s why people...obviously you need to use the blue, when you get wheezy you have to use the blue where the brown is not going to help you when you’re really short of breath. Umm and you could live by just doing that. You wouldn’t have to have that preventative if you used your blue when you needed it.

27f 10-9 High user

The purple disk preventer I don’t think about as much because I know I can survive without it.

27f 10-6 High user

Why do young adults with asthma overuse bronchodilator inhalers?

home, holiday luggage), and needing to send an email around the workplace to gain access to bronchodilators in an emergency.

High users more often held explanatory models of asthma where the function of the inhalers was solely to provide quick relief of symptoms by bronchodilation (box 8). Only 2 of 12 high users spontaneously cited prevention as a function, compared with 8 of 9 low users. This was reflected in the primacy of bronchodilator inhalers for this group—one described this as a process of ‘becoming completely blue’. These inhalers figured prominently in their thinking about asthma (box 9); they were seen as a tool to enable young people to get on with their busy lives—a quick fix...to have a couple of squirts and get back to what you are doing. The convenience of a single inhaler was reflected in comments such as ‘When I felt wheezy it [the inhaled steroid] didn’t stop it, the blue one does. Umm...so why carry two around when you can make do with one?’ The preference for short-acting bronchodilator inhalers was simple: ‘Yep. Quick fix, cheaper’. The primacy of bronchodilator inhalers might reflect their prescription as sole therapy at diagnosis: ‘Because you’re prescribed the blue one first. I mean I was given the Ventolin and that was it, sent packing.’

Some high users had insight into their inhaler use: “and it isn’t until you look back and think ‘Christ, I’m
doing it sixty or seventy times a day, God, what the hell am I up to? Umm, that’s when you sort of think…but like I say when I was at college and I couldn’t afford both, that’s why I always had the blue one. Umm, I never thought of buying a brown one in preference to the blue one…”

Cost of prescriptions for asthma medication

Most respondents expressed irritation at having to pay for asthma prescriptions. In the UK, medication is free only for children (aged less than 16 years), the elderly (over 60 years), the unemployed and certain risk groups (thyroid disorders and diabetes). Asthma was seen as a life-threatening condition, and as such should have medication provided free of cost. Cost was seen as a disincentive to obtaining prophylactic medication (box 10).

DISCUSSION

Principal findings

Asthma had a major impact on the lives of these young adults, most of whom were in their third decade. High users of short-acting bronchodilators described poor adaptation to their illness. They held explanatory models of asthma which focused on bronchodilation, with a minority mentioning prevention as a function of inhalers, or inflammation as a causal factor. Their preferential use of short-acting bronchodilators made sense to them: they were rapid, effective and cheap: a ‘quick-fix’ that enabled them to get on with their busy lives. All respondents were concerned about the cost of asthma medication and some were clear that this was a major disincentive to obtaining prophylactic medication. In the UK, adults over the age of 16 only receive free medication if they are unemployed, or in certain risk groups (eg, diabetes and hypothyroidism).

Strengths and weaknesses

The strengths of our study included a qualitative approach appropriate to the research question addressed, with a purposive sampling strategy of subjects designed to generate two groups of respondents that were reasonably (but not perfectly) matched across a range of variables. Interviews generated rich data and considerable insight into personal and sometimes intimate aspects of respondents’ lived experiences of asthma and the disruption it caused. A constant comparison approach allowed us to explore emerging themes as they arose. Reliability was aided by the full transcription of interviews, use of qualitative software that enabled tracking of the analysis, meetings to discuss and resolve coding differences, and the use of a structured approach (the Framework method) to analysis. Validity was supported by having data independently examined by a third author (a medical sociologist), who identified no additional themes. While our sample was relatively small, we achieved data saturation, the most important determinant of sample size in qualitative work. Our sample was drawn from a single general practice. While caution should be exercised in generalising findings from any qualitative work, the patients in this study are likely to be typical of any UK urban general practice.

Relevance to other work

To our knowledge, no other qualitative studies have examined this topic, or specifically this age group with asthma. While Gabe, studying schoolchildren, found that asthma sufferers generally adapted well to their illness, our data suggest that a minority of children with asthma strikingly fail to adapt to their illness as they reach young adulthood. Asthma caused significant disruption to their lives and aspirations, which was reflected in the feelings of anger, frustration and stigmatisation they expressed. These observations on the process of adaptation (or lack of it) echo those of Snadden who, in a sample of seven middle-aged Canadians with asthma, noted: ‘the path to acceptance varied, and not everyone was able to complete the journey’. Similarly, Adams, also studying an older age group with asthma, identified ‘deniers, accepters and pragmatists’. In a cross-sectional study, Diette found that emotional problems with asthma and the cancelling of social activities were both significantly more common in bronchodilator overusers.

In a qualitative study of people with asthma in Australia, Goeman et al. also found that paying for asthma medication could compromise adherence. For children in the USA aged over 5 years with asthma, the more parents had to pay for medication, the less medication was used and the greater was the likelihood of hospitalisation. Interestingly, qualitative work in older people with asthma suggests that those in whom asthma...
was diagnosed when treatment options were few can have a wider range of treatment strategies.22

Clinical relevance

These data suggest that considerable benefit could accrue from improving the asthma control achieved by young adults who overuse bronchodilators. A number of strategies might achieve this.

First, more effective education, especially at the time of diagnosis, but also at routine review, could focus on helping young people accept and adapt to their illness as well as helping them to develop an explanatory model of asthma that focuses on prevention using anti-inflammatory medication rather than quick relief via bronchodilators.23 Qualitative studies show that people with asthma value a preventive approach to care and, moreover, both seek and benefit from the formation of a partnership approach with their physician.24 25 There is currently limited evidence that specifically psychological interventions can improve symptoms and reduce hospital admissions for asthma.26 27

Negative images of people with asthma are common. Reducing stigmatisation might help people with asthma feel more comfortable about using inhalers in public. This too could improve adaptation and acceptance.

Finally, strategies that might increase the use of preventive anti-inflammatory treatment in this age group include promoting the use of a single anti-inflammatory/bronchodilator combination inhaler,28 and providing free asthma medication. Further studies are needed to determine the impact of these strategies on asthma morbidity.

Acknowledgements

We are grateful to the respondents for participating in this study.

Contributors SC and CG conceived the idea for the study and elaborated the study design. SC carried out interviews, which were coded by SC and CG. CG and SC were responsible for the data analysis, to which CS contributed critical input. CG prepared the first draft of the manuscript, including constructing boxes of illustrative quotes, with SC and CS providing critical comment. CG is the guarantor. All authors read and approved the final manuscript.

Funding This work was supported by a grant from NELCRAD.

Competing interests None.

Patient consent Obtained.

Ethics approval Essex Local Research Ethics Committee (REC MH428).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Data from this study consisting of unpublished interview transcripts are available on request from c.j.griffiths@qmul.ac.uk.

REFERENCES


'The blue one takes a battering' why do young adults with asthma overuse bronchodilator inhalers? A qualitative study
Sue Cole, Clive Seale and Chris Griffiths

BMJ Open 2013 3:
doi: 10.1136/bmjopen-2012-002247

Updated information and services can be found at:
http://bmjopen.bmj.com/content/3/2/e002247

These include:

Supplementary Material
Supplementary material can be found at:
http://bmjopen.bmj.com/content/suppl/2013/02/15/bmjopen-2012-00247.DC1

References
This article cites 24 articles, 6 of which you can access for free at:
http://bmjopen.bmj.com/content/3/2/e002247#BIBL

Open Access
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

General practice / Family practice (637)
Health policy (646)
Health services research (1407)
Patient-centred medicine (454)
Qualitative research (676)
Respiratory medicine (332)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/